Expansion Opportunity BioDot recently expanded its Irvine headquarters, signaling growth and increased capacity. This presents a chance to engage on updated instrumentation needs, service contracts, and potential onboarding of additional microfluidic and diagnostic deployments in North America.

Diagnostic Scale With BioDot producing over 3 billion diagnostic tests annually and strong presence in lateral flow, immunoassays, and FISH-based workflows, there is a clear opportunity to broaden reagent handling, automation, and assay development partnerships for high-volume diagnostics programs.

Strategic Partnerships Recent collaboration with Empire Genomics to develop FISH probe panels indicates openness to co-development and platform-specific consumables. Engage for family-of-products expansions, validation services, and joint go-to-market for cytogenetics and molecular diagnostics.

Automation Leadership BioDot’s focus on precision dispensing across picoliter to microliter ranges, including CellWriter systems and Lyobead workflows, suggests opportunities to upsell with higher-throughput modules, consumables, and software integrations for labs expanding automation footprints.

Global Reach Serving customers in the US, China, the UK, Europe, and beyond, BioDot is positioned to discuss regional regulatory support, localized service, and cross-border supply chain solutions to support multinational diagnostics and biopharma collaborations.